We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine (LYNX)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01159743
First Posted: July 9, 2010
Last Update Posted: January 24, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Demométrica
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
Results First Submitted: September 28, 2012  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Cross-Sectional
Condition: HIV Infection

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Efavirenz Human Immunodeficiency Virus 1 (HIV-1)-infected patients on initial and continuous antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
Lopinavir / Ritonavir HIV-infected patients on initial and continuous antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).

Participant Flow:   Overall Study
    Efavirenz   Lopinavir / Ritonavir
STARTED   237   109 
COMPLETED   237   109 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Efavirenz Human Immunodeficiency Virus 1 (HIV-1)-infected patients on initial and continuous antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
Lopinavir / Ritonavir HIV-infected patients on initial and continuous antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
Total Total of all reporting groups

Baseline Measures
   Efavirenz   Lopinavir / Ritonavir   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 237   109   346 
Age [1] 
[Units: Years]
Mean (Standard Deviation) 		 42.2  (9.74)   44.3  (9.46)   42.8  (9.69) 
[1] Data available for 235 and 109 patients in each treatment group respectively, 344 total patients.
Gender 
[Units: Participants]
 		     
Female   38   17   55 
Male   199   92   291 
Region of Enrollment 
[Units: Participants]
 		     
Spain   237   109   346 
Hepatitis C Virus (HCV) Co-infection 
[Units: Participants]
 		     
HCV positive   41   33   74 
HCV negative   196   76   272 
Time on current antiretroviral regimen 
[Units: Participants]
 		     
2 - 3 years   75   27   102 
3 - 4 years   76   32   108 
More than 4 years   86   50   136 
Undetectable HIV-1 RNA (< 50 copies/mL) [1] 
[Units: Participants]
 		 236   109   345 
[1] Data available for 236 and 109 patients in each treatment group respectively, 345 total patients.
Cluster of differentiation 4 (CD4)+ T-cell count [1] 
[Units: cells/µL]
Mean (Standard Deviation) 		 585.56  (246.87)   592.75  (258.77)   587.82  (250.31) 
[1] Data available for 236 and 108 patients in each treatment group respectively, 344 total patients.
CD4+ T-cell count nadir [1] 
[Units: cells/µL]
Mean (Standard Deviation) 		 216.85  (121.88)   169.94  (153.84)   202.00  (134.39) 
[1] Data available for 231 and 107 patients in each treatment group respectively, 338 total patients.
Previous acquired immunodeficiency syndrome (AIDS) diagnosis [1] 
[Units: Participants]
 		     
Yes   39   34   73 
No   198   74   272 
[1] Data available for 237 and 108 patients in each treatment group respectively, 345 total patients.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Total Limb Fat Mass   [ Time Frame: Study visit ]
  Show Outcome Measure 1

2.  Secondary:   Distribution of Body Fat Mass   [ Time Frame: Study visit ]
  Show Outcome Measure 2

3.  Secondary:   Lipodystrophy Severity Grading Scale (LSGS) Scores   [ Time Frame: Study visit ]
  Show Outcome Measure 3

4.  Secondary:   Change Over Time in Body Fat Distribution   [ Time Frame: DEXA performed at the study visit and more than 6 months prior to the study visit (the period of time between the DEXA recorded at the study visit and the previous DEXA ranged from 6 to 36 months). ]
  Show Outcome Measure 4


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Reporting Groups
  Description
Efavirenz Human Immunodeficiency Virus 1 (HIV-1)-infected patients on initial and continuous antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
Lopinavir / Ritonavir HIV-infected patients on initial and continuous antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).

Serious Adverse Events
    Efavirenz   Lopinavir / Ritonavir
Total, Serious Adverse Events     
# participants affected / at risk   0/237 (0.00%)   0/109 (0.00%) 




  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Show More Information